预测非小细胞肺癌免疫治疗疗效的生物学指标研究进展
摘要
高。免疫检查点抑制剂（ICIs）的出现极大程度上改善了NSCLC患者的预后，然而临床上只有少数患者能够获得长
期获益。因此，有必要探索NSCLC免疫治疗的有效预测性生物学指标。近年来随着分子生物学、基因组测序技术的
发展和肿瘤及宿主免疫微环境的研究不断深入，相关成果繁多。本文围绕NSCLC免疫治疗疗效的预测生物学指标进
行综述，为精准免疫治疗提供参考。
关键词
全文:
PDF参考
[1]SIEGEL R, GIAQUINTO A N, JEMAL A. Cancer
statistics, 2024[J]. CA A Cancer J Clin, 2024, 74: 12-49.
DOI: 10.3322/caac.21820.
[2]RECK M, REMON J, HELLMANN M D. First_xfffe_line immunotherapy for non-small-cell lung cancer[J]. J Clin
Oncol, 2022, 40(6): 586-597. DOI: 10.1200/JCO.21.01497.
[3]ZHU L,WANG T,WU J,et al. Updated interpretation
of the NCCN clinical practice guidelines ( version 3. 2023)
for non-small cell lung cancer[J]. Chinese Journal of Lung
Cancer,2023,26(6):407-415.
[4]SUN JY,ZHANG D,WU S,et al. Resistance to
PD-1/PD-L1 blockade cancer immunotherapy: mechanisms,
predictive factors, and future perspectives[J]. Biomark Res,
2020,8:35.
[5]Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab
versus chemotherapy for previously untreated, PD-L1-
ex pressing, locally advanced or metastatic non-small cell
lung cancer (KEYNOTE-042): a randomised, open-label,
controlled, phase 3 trial. Lancet, 2019, 393(10183): 1819-
1830. doi: 10.1016/s0140-6736(18)32409-7
[6]Spiliotaki M, Neophytou CM, Vogazianos P, et al.
Dynamic monitoring of PD-L1 and Ki67 in circulating tumor
cells of metastatic non-small cell lung cancer patients treated
with pembrolizumab[J]. Mol Oncol, 2023, 17(5): 792-809.
[7]Bracci S, Dolciami M, Trobiani C, et al. Quantitative
CT texture analysis in predicting PD-L1 expression in locally
advanced or metastatic NSCLC patients[J]. La radiologia
Medica, 2021, 126(11): 1425-1433.
[8]Hellmann MD, Ciuleanu TE , Pluzanski A , et al.
Nivolumab plus Ipilimumab in lung cancer with a high tumor
mutational burden. N Engl J Med, 2018, 378(22): 2093-
2104. doi: 10.1056/NEJMoa1801946
[9]Zeinalian M, Hashemzadeh-Chaleshtori M, Salehi R,
et al. Clinical Aspects of Microsatellite Instability Testing in
Colorectal Cancer[J]. Adv Biomed Res, 2018, 7: 28.
[10]王春华，王苏杭，许建秋，等.非小细胞肺癌组
织中DNA错配修复蛋白的表达及与临床病理特征的关系
[J].浙江医学，2023，45（24）：2642-2646.
[11]Warth A, Körner S, Penzel R, et al. Microsatellite
instability in pulmonary adenocarcinomas: a comprehensive
study of 480 cases[J]. Virchows Arch, 2016, 468(3): 313-319.
[12]Tan Q, Wang D, Yang J, Xing P, Yang S, Li Y, et
al. Autoantibody profiling identifies predictive biomarkers of
response to anti-PD1 therapy in cancer patients. Theranostics
(2020) 10(14):6399-410.
[13]Juan Zhou,Jing Zhao,Qingzhu Jia,et al. Peripheral
Blood Autoantibodies Against to Tumor-Associated Antigen
Predict Clinical Outcome to Immune Checkpoint Inhibitor_xfffe_Based Treatment in Advanced Non-Small Cell Lung
Cancer[J].forntiers in Oncology,2021,3(11):1-9.
[14]Kang DH, Park CK, Chung C, et al. Baseline
serum interleukin-6 levels predict the response of patients
with advanced non-small cell lung cancer to PD-1/PD-L1
inhibitors[J].Immune Netw,2020,20(3):e27.
[15]Keegan A, Ricciuti B, Garden P, et al. Plasma IL-6
36
changes correlate to PD-1 inhibitor responses in NSCLC[J].J
Immunother Cancer,2020,8(2):e000678.
[16]Kauffmann-Guerrero D, Kahnert K, Kiefl R, et
al. Systemic in-flammation and pro-inflammatory cytokine
profile predict response to checkpoint inhibitor treatment in
NSCLC:a prospective study[J].Sci Rep,2021,11(1):10919.
[17]Shi Y, Liu X, Du J, et al. Circulating cytokines
associated with clinical outcomes in advanced non-small cell
lung cancer patients who received chemoimmunotherapy [J].
Thorac Cancer,2022,13(2):219-227.
[18]LIU X H, YIN L J, SHEN S N, et al. Inflammation
and cancer: paradoxical roles in tumorigenesis and implications
in immunotherapies[J]. Genes Dis, 2023, 10(1): 151-164.
[19]LIU J Y, GENG X F, HOU J X, et al. New
insights into M1/M2 macrophages: key modulators in cancer
progression[J]. Cancer Cell Int, 2021, 21(1): 389.
[20]Antunes-ferreira M, D’Ambrosi S, Arkani M,
et al. Tumor-educated platelet blood tests for non-small
cell lung cancer detection and management[J]. Sci Rep,
2023,13(1):9359.
[21]马婷，李君哲，黄良玖，等.全身免疫营养炎症
指标预测PD-1免疫治疗非小细胞肺癌的效果分析[J].南
昌大学学报，2024，64（5）：69-73.
[22]Ancel J, Dormoy V, Raby BN, et al. Soluble
biomarkers to predict clinical outcomes in non-small cell
lung cancer treated by immune checkpoints inhibitors . Front
Immunol, 2023,14:1171649.
[23]娄俊，易韵，储小燕，等.70例卵巢癌患者治疗
期间外周血T淋巴细胞亚群测定的临床意义[J].实用癌症
杂志，2022，37（5）：780-782.
[24]Al-Shibli KI, Donnem T, Al-Saad S, et al.
Prognostic effect of epithelial and stromal lymphocyte
infiltration in non-small cell lung cancer[J]. Clinical cancer
research: an official journal of the American Association for
Cancer Research,2008,14(16):5220-7.
[25]鲍千红，吕凌云，张伟群，等 . 过敏性鼻炎患
者血清中炎症因子、免疫球蛋白及T淋巴细胞亚群水
平检测及分析 [J]. 中国卫生检验杂志，2020，30（21）：
2614-2616.
[26]吕清芳，张鹏，李桂香.PD-1单抗联合化疗对
非小细胞肺癌患者淋巴细胞亚群的影响及疗效和预后的
相关分析[J].中国肿瘤生物治疗杂志，2025，32（1）：
73-78.
[27]胡姗姗，李醒亚，向梅，等.白蛋白与碱性磷酸
酶比值对非小细胞肺癌患者临床结局的预测价值分析[J].
医药论坛杂志，2022，43（6）：1-4.
[28]李蔚.非小细胞肺癌患者免疫治疗前后疾病相关
指标水平变化及疗效相关影响因素分析[J].现代医学与健
康研究，2023，7（7）：116-118.
[29]WANG Y, ZHAO N, WU Z B, et al. New
insight on the correlation of metabolic status on 18FFDG PET/CT with immune marker expression in patients
with non-small cell lung cancer[J]. Eur J Nucl Med Mol
Imaging,2020,47(5):1127-1136.
[30]KAIRA K,HIGUCHI T,NARUSE I,et al.
Metabolic activity by 18F-FDG-PET/CT is predictive
of early response after nivolumab in previously treated
NSCLC[J].Eur J Nucl Med Mol Imaging,2018,45(1):56-66.
[31]张璐锦.糖脂代谢与非小细胞肺癌免疫检查点抑
制剂疗效关系的研究[D].开封：河南大学，2023.
[32]尚士洁.晚期非小细胞肺癌患者血脂水平与免疫
治疗疗效的相关性研究[D].济南：山东大学，2023.
[33]Zhao H, Li D, Liu J, et al. Bifidobacterium breve
predicts the efficacy of anti-PD-1 immunotherapy combined
with chemotherapy in Chinese NSCLC patients[J]. Cancer
Med, 2023, 12(5): 6325-6336.
[34]Jin Y, Dong H, Xia L, et al. The Diversity of Gut
Microbiome is Associated With Favorable Responses to AntiProgrammed Death 1 Immunotherapy in Chinese Patients
With NSCLC[J]. J Thorac Oncol, 2019, 14(8): 1378-1389.
Refbacks
- 当前没有refback。
